Metoprololsuccinaat Sandoz (Metoprolol Succinate)

Metoprolol succinate blocks β1‑adrenergic receptors in the heart, preventing catecholamines from increasing heart rate and contractility. This results in reduced cardiac output, lower blood pressure, and decreased oxygen demand by the myocardium, which benefits patients with high blood pressure, angina, and heart failure.

The appropriate dose of Metoprololsuccinaat Sandoz is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and renal function. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for metoprolol succinate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprolol succinate is a long‑acting, cardio‑selective β1‑blocker, offering once‑daily dosing and a smoother heart‑rate control compared with non‑selective agents. Its selectivity reduces the likelihood of bronchospasm, making it preferable for patients with respiratory concerns, while still providing effective blood‑pressure and anti‑anginal control.

Metoprololsuccinaat Sandoz should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. This helps maintain tablet integrity and potency throughout its shelf life.

The medication is taken orally, usually once daily, with or without food as directed by a healthcare professional. Swallow the tablet whole with a glass of water and do not crush or chew it unless specifically instructed.

Serious adverse events can include severe bradycardia, heart block, marked hypotension, bronchospasm in susceptible individuals, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience fainting, extreme fatigue, difficulty breathing, or swelling of the face or throat.

Metoprololsuccinaat Sandoz is contraindicated in patients with known hypersensitivity to metoprolol or any excipients, those with severe sinus bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and individuals in cardiogenic shock. It should also be used with caution in patients with severe asthma or chronic obstructive pulmonary disease.